Festering dispute on HCV patent

A former Centers for Disease Control scientist has taken to court his long-simmering dispute with Chiron Corp. over its U.S. hepatitis C virus patent, taking on the company with perhaps the most methodical and aggressive patent strategy in the industry.

The suit, filed by Daniel Bradley, seeks to invalidate CHIR's 5,530,671 patent, and asks that the patent be modified to include Bradley as a co-inventor. The complaint also seeks damages from the company.